T. Rowe Price Associates
IMCR icon

T. Rowe Price Associates’s Immunocore IMCR Stock Holding History

T. Rowe Price Associates’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Sell
831,068
-88,264
-10% -$2.61M ﹤0.01% 1071
2026
Q1 		$27.7M Sell
919,332
-49,452
-5% -$1.6M ﹤0.01% 952
2025
Q4 		$33.6M Sell
968,784
-47,987
-5% -$1.69M ﹤0.01% 933
2025
Q3 		$36.9M Buy
1,016,771
+11,179
+1% +$380K ﹤0.01% 883
2025
Q2 		$31.6M Sell
1,005,592
-882,348
-47% -$27.4M ﹤0.01% 854
2025
Q1 		$56M Sell
1,887,940
-299,590
-14% -$8.99M 0.01% 694
2024
Q4 		$64.5M Buy
2,187,530
+29,832
+1% +$943K 0.01% 673
2024
Q3 		$67.2M Sell
2,157,698
-674,971
-24% -$24.5M 0.01% 669
2024
Q2 		$96M Buy
2,832,669
+395,085
+16% +$20.2M 0.01% 551
2024
Q1 		$158M Sell
2,437,584
-506,990
-17% -$34.8M 0.02% 465
2023
Q4 		$201M Buy
2,944,574
+423,290
+17% +$22M 0.03% 420
2023
Q3 		$131M Buy
2,521,284
+97,864
+4% +$5.79M 0.02% 465
2023
Q2 		$145M Buy
2,423,420
+1,039,980
+75% +$59.4M 0.02% 452
2023
Q1 		$68.4M Buy
1,383,440
+49,524
+4% +$2.78M 0.01% 602
2022
Q4 		$76.1M Buy
1,333,916
+170,355
+15% +$9.59M 0.01% 550
2022
Q3 		$54.6M Buy
1,163,561
+849,662
+271% +$40.5M 0.01% 624
2022
Q2 		$11.7M Sell
313,899
-29,380
-9% -$954K ﹤0.01% 1298
2022
Q1 		$10.3M Sell
343,279
-36,612
-10% -$924K ﹤0.01% 1364
2021
Q4 		$13M Buy
379,891
+17,865
+5% +$647K ﹤0.01% 1368
2021
Q3 		$13.4M Sell
362,026
-5,278
-1% -$178K ﹤0.01% 1384
2021
Q2 		$14.3M Sell
367,304
-20,608
-5% -$796K ﹤0.01% 1369
2021
Q1 		$16.5M Buy
+387,912
New +$17.3M ﹤0.01% 1317

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

T. Rowe Price Associates's IMCR Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Immunocore (IMCR) stake by 9.6% in Q2 2026, selling an estimated $2.61M and leaving 831,068 shares worth $26.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

T. Rowe Price Associates first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. The position peaked at $201M in Q4 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • T. Rowe Price Associates held 831,068 shares of Immunocore worth $26.4M as of Q2 2026.
  • T. Rowe Price Associates sold 88,264 Immunocore shares in Q2 2026, an estimated $2.61M.
  • Immunocore made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1071 holding.
  • T. Rowe Price Associates first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Immunocore position peaked at $201M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.